The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V51871 | Leritrelvir (RAY1216) | 2923310-64-7 | Leritrelvir (RAY1216) is an orally bioactive slow inhibitor of the major SARS-CoV-2 protease with Ki of 8.6 nM. |
|
V51851 | Lomtegovimab (BI 767551; DZIF-10c) | 2550869-33-3 | Lomtegovimab (BI 767551) is a humanized anti-SARS-COV-2 spike glycoprotein monoclonal antibody (mAb). |
|
V52605 | Lopinavir-d8 | 1224729-35-4 | Lopinavir-d8 is the deuterium labelled form of Lopinavir. |
|
V23686 | LY1 | 2883813-32-7 | LY1 is a potent and specific covalent inhibitor against SARS-CoV-2 PLpro and Mpro, with Kds of 1.5 μM and 2.3 μM for Mpro C145A protein and PLpro C111A protein, respectively. |
|
V76089 | M56-S2 iodide | 1101867-17-7 | M56-S2 iodide is a SARS-CoV-2 Mpro inhibitor (IC50=4.0 μM). |
|
V80900 | Maniwamycin E | Maniwamycin E is a Maniwamycin analogue that can be extracted from a culture extract of Streptomyces thermotolerans. | |
|
V51813 | Masavibart (ZRC3308-A7) | 2640223-84-1 | Masavibart (ZRC3308-A7) is a monoclonal antibody (mAb) (IgG1 type) targeting SARS-CoV-2. |
|
V80688 | MAT-POS-e194df51-1 | MAT-POS-e194df51-1 is an orally bioactive, non-covalent and non-peptide SARS-CoV-2 main protease (Mpro) inhibitor (antagonist) with IC50 of 37nM. | |
|
V85189 | MDOLL-0229 | ||
|
V2392 | Merafloxacin | 91188-00-0 | Merafloxacin (CI-934; CI934; CI 934), an antibacterial belonging to the fluoroquinolone class, is a novel and potent −1 PRF (programmed -1 ribosomal frameshifting) inhibitor of SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2). |
|
V52894 | MERS-CoV-IN-1 | 2245697-92-9 | MERS-CoV-IN-1 could be utilized as an active molecular composition to prevent diseases caused by MERS-CoV and SARS viruses. |
|
V54416 | Methyl tanshinonate | 18887-19-9 | Methyl tanshinonate is a tanshinone that can be extracted from the Salvia miltiorrhiza (S. |
|
V79353 | Methylprednisolone-d3 (U 7532-d3) | Methylprednisolone-d3 is the deuterium labelled form of Methylprednisolone. | |
|
V76062 | Mindeudesivir hydrobromide (JT001; VV116; GS-621763-d1 hydrobromide) | 2779498-79-0 | Mindeudesivir (JT001; VV116; GS-621763-d1) HBr, an analogue of Remdesivir, is a highly orally bioactive nucleoside antiviral compound against SARS-CoV-2 and respiratory syncytial virus (RSV) infection . |
|
V83615 | MK-7845 | 2952554-69-5 | |
|
V37654 | ML188 | 1417700-13-0 | ML188 is a potent and selective non-covalent SARS-CoV 3CLpro inhibitor with an IC50 of 1.5 μM. |
|
V41184 | MM3122 | 2574390-27-3 | MM3122 is a selective inhibitor of type II transmembrane serine protease (TMPRSS2) with IC50 of 0.34 nM. |
|
V37614 | Molnupiravir (EIDD-2801, MK-4482) | 2349386-89-4 | Molnupiravir (EIDD-2801;MK4482; prodrug-EIDD1931;MK-4482; trade name Lagevrio) is a novel, potent and orally bioavailable prodrug of the ribonucleoside analog EIDD-1931 with a broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as COVID-19, SARS-CoV-2, MERS-CoV, SARS-CoV. |
|
V53152 | Molnupiravir (EIDD-2801; MK-4482) | 2492423-29-5 | Molnupiravir (EIDD-2801) is the orally bioavailable isopropyl ester precursor of the ribonucleoside analog EIDD-1931. |
|
V76756 | Molnupiravir-d7 (EIDD-2801-d7; MK-4482-d7) | Molnupiravir-d7 is a deuterated marker of Molnupiravir. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
